DD Waters, C Brotons, CW Chiang, J Ferrières, JA Foody, JW Jukema, ...
Circulation 120 (1), 28-34, 2009
|Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in …|
H Sillesen, P Amarenco, MG Hennerici, A Callahan, LB Goldstein, J Zivin, ...
Stroke 39 (12), 3297-3302, 2008
|Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.|
SH Preskorn, J Alderman, M Chung, W Harrison, M Messig, S Harris
Journal of clinical psychopharmacology, 1994
|Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes|
DD Waters, JE Ho, SM Boekholdt, DA DeMicco, JJP Kastelein, M Messig, ...
Journal of the American College of Cardiology 61 (2), 148-152, 2013
|Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder|
EH Cook, KD Wagner, JS March, J Biederman, P Landau, R Wolkow, ...
Journal of the American Academy of Child & Adolescent Psychiatry 40 (10 …, 2001
|Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor …|
P Rossignol, D Dobre, JJV McMurray, K Swedberg, H Krum, ...
Circulation: Heart Failure 7 (1), 51-58, 2014
|Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial|
LB Goldstein, P Amarenco, J Zivin, M Messig, I Altafullah, A Callahan, ...
Stroke 40 (11), 3526-3531, 2009
|Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma volume: observations from the REVERSAL …|
SH Choi, A Chae, E Miller, M Messig, F Ntanios, AN DeMaria, SE Nissen, ...
Journal of the American College of Cardiology 52 (1), 24-32, 2008
|Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial|
N Mauras, OH Pescovitz, V Allada, M Messig, MP Wajnrajch, B Lippe
The Journal of Clinical Endocrinology & Metabolism 90 (7), 3946-3955, 2005
|Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol …|
LB Goldstein, P Amarenco, M LaMonte, S Gilbert, M Messig, A Callahan, ...
Stroke 39 (9), 2444-2448, 2008
|Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant|
C Parkinson, P Burman, M Messig, PJ Trainer
The Journal of Clinical Endocrinology & Metabolism 92 (1), 190-195, 2007
|Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial|
P Amarenco, LB Goldstein, M Messig, BJ O'Neill, A Callahan III, ...
Stroke 40 (7), 2486-2492, 2009
|Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials|
C Jimenez, P Burman, R Abs, DR Clemmons, WM Drake, KR Hutson, ...
European Journal of Endocrinology 159 (5), 517, 2008
|Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial|
K Fagerström, H Gilljam, M Metcalfe, S Tonstad, M Messig
Bmj 341, c6549, 2010
|Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder|
KD Wagner, EH Cook, H Chung, M Messig
Journal of child and adolescent psychopharmacology 13 (2, Supplement 1), 53-60, 2003
|Low-and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2|
RD Santos, DD Waters, L Tarasenko, M Messig, JW Jukema, J Ferrières, ...
American heart journal 158 (5), 860-866, 2009
|Pharmacokinetics and pharmacodynamics of extended‐release glipizide GITS compared with immediate‐release glipizide in patients with type II diabetes mellitus|
M Chung, I Kourides, W Canovatchel, T Sutfin, M Messig, RL Chaiken
The Journal of Clinical Pharmacology 42 (6), 651-657, 2002
|Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial|
P Amarenco, A Callahan III, VM Campese, LB Goldstein, MG Hennerici, ...
Stroke 45 (10), 2974-2982, 2014
|Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial|
P Raskin, C Huffman, C Toth, MJ Asmus, M Messig, RJ Sanchez, L Pauer
The clinical journal of pain 30 (5), 379-390, 2014
|A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2|
RD Santos, DD Waters, L Tarasenko, M Messig, JW Jukema, CW Chiang, ...
Atherosclerosis 224 (1), 150-153, 2012